2013-03-07 14:14:19 - SADIF-Investment Analytics has applied its StockMarks™ stock-rating system to Anhui Anke Biotechnology (Group) Co Ltd and produced a Rating Update Report, rating the company's attractiveness to long-term investors.

Ilhavo, Portugal – SADIF Investment Analytics, announces a new Rating Update Report covering Anhui Anke Biotechnology (Group) Co Ltd (300009). The report uses SADIF's powerful StockMarks™ stock rating system and contains important analysis for any current or potential Anhui Anke Biotechnology (Group) Co Ltd investor.

Report Summary: Anhui Anke Biotechnology (Group) Co Ltd is an above average quality company with a positive outlook. Anhui Anke Biotechnology (Group) Co Ltd has strong business growth and is run by efficient management. The trend in Anhui Anke Biotechnology (Group) Co Ltd fair value exchange rate against its closest rated-competitor, Shanghai Kehua Bio-Engineering Co., Ltd., has been depreciating over the past 2 weeks. When compared to its closest competitor, Anhui Anke Biotechnology (Group) Co Ltd

shows similar overvaluation and is equally likely to outperform the market.

The 3-page report breaks down the Total StockMark into its three components – business, management and price, performing an in-depth analysis of Anhui Anke Biotechnology (Group) Co Ltd for long-term investors.

The report has been distributed to Thomson Reuters. It is available in Investext from multiple professional platforms including Thomson Research, Thomson ONE Banker, DIALOG/INTELLISCOPE, Thomson Gale, West Services, Advisen, Alacra-Datadownlink, Factiva, INTERNET SECURITIES and LEXIS/NEXIS or directly from SADIF-Investment Analytics at:
www.sadifanalytics.com/stockmarks/company-ru-21-300009

About SADIF-Investment Analytics:
SADIF-Investment Analytics is an independent investment research company covering sixteen different markets and over 12,000 companies. The StockMarks™ system is based on proven investment principles and is designed to drive long-term shareholder returns.